Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 192

1.

IgG4-Related Sclerosing Cholangitis and Primary Sclerosing Cholangitis.

Tanaka A.

Gut Liver. 2018 Sep 13. doi: 10.5009/gnl18085. [Epub ahead of print] Review.

2.

Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.

Lemoinne S, Pares A, Reig A, Ben Belkacem K, Kemgang Fankem AD, Gaouar F, Poupon R, Housset C, Corpechot C, Chazouillères O.

Clin Res Hepatol Gastroenterol. 2018 Aug 9. pii: S2210-7401(18)30121-9. doi: 10.1016/j.clinre.2018.06.009. [Epub ahead of print]

PMID:
30100231
3.

Possible roles of basophils in chronic itch.

Hashimoto T, Rosen JD, Sanders KM, Yosipovitch G.

Exp Dermatol. 2018 Jun 12. doi: 10.1111/exd.13705. [Epub ahead of print]

PMID:
29894005
4.

Characteristics and Outcomes Reported by Patients With Primary Sclerosing Cholangitis Through an Online Registry.

Kuo A, Gomel R, Safer R, Lindor KD, Everson GT, Bowlus CL.

Clin Gastroenterol Hepatol. 2018 Apr 26. pii: S1542-3565(18)30409-9. doi: 10.1016/j.cgh.2018.04.047. [Epub ahead of print]

PMID:
29705262
5.

Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2-/- mice by modulating composition, signalling and excretion of faecal bile acids.

Fuchs CD, Paumgartner G, Mlitz V, Kunczer V, Halilbasic E, Leditznig N, Wahlström A, Ståhlman M, Thüringer A, Kashofer K, Stojakovic T, Marschall HU, Trauner M.

Gut. 2018 Sep;67(9):1683-1691. doi: 10.1136/gutjnl-2017-314553. Epub 2018 Apr 10.

6.

Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study.

Webb GJ, Rahman SR, Levy C, Hirschfield GM.

Aliment Pharmacol Ther. 2018 Apr;47(8):1213-1219. doi: 10.1111/apt.14579. Epub 2018 Feb 22.

7.

Primary sclerosing cholangitis.

Dyson JK, Beuers U, Jones DEJ, Lohse AW, Hudson M.

Lancet. 2018 Jun 23;391(10139):2547-2559. doi: 10.1016/S0140-6736(18)30300-3. Epub 2018 Feb 13. Review.

PMID:
29452711
8.

Pregnant Lady With Undiagnosed Hodgkin's Disease Presenting As Secondary Sclerosing Cholangitis.

Khattak T, Ali Shah SH, Khan W, Raza SS, Ahmad U, Ullah F.

J Ayub Med Coll Abbottabad. 2017 Oct-Dec;29(4):684-685.

9.

New therapies target the toxic consequences of cholestatic liver disease.

Jansen PLM.

Expert Rev Gastroenterol Hepatol. 2018 Mar;12(3):277-285. doi: 10.1080/17474124.2018.1424538. Epub 2018 Jan 10. Review.

PMID:
29310470
10.

Complications, symptoms, quality of life and pregnancy in cholestatic liver disease.

Zakharia K, Tabibian A, Lindor KD, Tabibian JH.

Liver Int. 2018 Mar;38(3):399-411. doi: 10.1111/liv.13591. Epub 2017 Oct 3. Review.

PMID:
28921801
11.

Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial.

Bolier R, de Vries ES, Parés A, Helder J, Kemper EM, Zwinderman K, Elferink RPO, Beuers U; Netherlands Association for the Study of the Liver (NASL) Cholestatic Liver Diseases Study Group.

Trials. 2017 May 23;18(1):230. doi: 10.1186/s13063-017-1966-8.

12.

norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.

Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Färkkilä M, Schramm C, Spengler U, Chapman R, Bergquist A, Schrumpf E, Nevens F, Trivedi P, Reiter FP, Tornai I, Halilbasic E, Greinwald R, Pröls M, Manns MP, Trauner M; European PSC norUDCA Study Group.

J Hepatol. 2017 Sep;67(3):549-558. doi: 10.1016/j.jhep.2017.05.009. Epub 2017 May 18.

13.

Immunosuppressive Agents for the Treatment of Primary Sclerosing Cholangitis: A Systematic Review and Meta-Analysis.

Peng X, Luo X, Hou JY, Wu SY, Li LZ, Zheng MH, Wang LY.

Dig Dis. 2017;35(5):478-485. doi: 10.1159/000471874. Epub 2017 May 6. Review.

PMID:
28478443
14.

Advances in primary sclerosing cholangitis.

Horsley-Silva JL, Carey EJ, Lindor KD.

Lancet Gastroenterol Hepatol. 2016 Sep;1(1):68-77. doi: 10.1016/S2468-1253(16)30010-3. Epub 2016 Aug 10. Review.

PMID:
28404115
15.

Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.

Hegade VS, Jones DE, Hirschfield GM.

Dig Dis. 2017;35(3):267-274. doi: 10.1159/000450988. Epub 2017 Mar 1. Review.

PMID:
28249258
16.

Clinical Features, Response to Treatment, and Outcomes of IgG4-Related Sclerosing Cholangitis.

Tanaka A, Tazuma S, Okazaki K, Nakazawa T, Inui K, Chiba T, Takikawa H.

Clin Gastroenterol Hepatol. 2017 Jun;15(6):920-926.e3. doi: 10.1016/j.cgh.2016.12.038. Epub 2017 Jan 20.

PMID:
28111336
17.

Diagnostic considerations for cholestatic liver disease.

Pollock G, Minuk GY.

J Gastroenterol Hepatol. 2017 Jul;32(7):1303-1309. doi: 10.1111/jgh.13738. Review.

PMID:
28106928
18.

A Triple Blinded, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis: a Pilot Study.

Rahimpour S, Nasiri-Toosi M, Khalili H, Ebrahimi-Daryani N, Nouri-Taromlou MK, Azizi Z.

J Gastrointestin Liver Dis. 2016 Dec;25(4):457-464. doi: 10.15403/jgld.2014.1121.254.rah.

19.
20.

Cholestatic Liver Injury: Care of Patients With Primary Biliary Cholangitis or Primary Sclerosing Cholangitis.

Larson L, James M, Gossard A.

AACN Adv Crit Care. 2016 Oct;27(4):441-452.

PMID:
27959300

Supplemental Content

Loading ...
Support Center